Factor V Leiden or prothrombin G20210A mutation in healthy adults and adults research hub

A phase 1 trial in healthy adults and adults with increased inherited risk of developing blood clots

This study is testing a new medicine, CITY-FXI, for the very first time in people. It aims to prevent dangerous blood clots with less risk of bleeding than current treatments. We're looking for healthy adults and those with a higher risk of clots to help us learn about its safety and effects.